Improved method to calculate the antibody avidity index

Journal of Clinical Laboratory Analysis

Volumn 21, Issue 3, 2007, Pages 201-206

  Perciani, C T ^a   Peixoto, P S ^b   Dias, W O ^a   Kubrusly, F S ^a   Tanizaki, M M ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Meningococcal vaccine; Oil water emulsion; Outer membrane vesicle; Porcine pulmonary surfactant

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN; LUNG SURFACTANT; MENINGOCOCCUS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OUTER MEMBRANE PROTEIN; WATER OIL CREAM;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CALCULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; MATHEMATICAL ANALYSIS; MEMBRANE VESICLE; MENINGOCOCCEMIA; MOUSE; NONHUMAN; STANDARD; SWINE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODY AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN G; MICE; PROTEIN DENATURATION; REPRODUCIBILITY OF RESULTS; THIOSULFATES;

SUS;

EID: 34249327274     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20172     Document Type: Article

References (24)

1. Hedman K, Lappalainen M, Seppaia I, Makela O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 1989;159:736-740.
2. Wilson KM, Di Camili C, Doughty L, Dax EM. Humoral response to primary rubella virus infection. Clin Vaccine Immunol 2006;13:380-386.
3. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of a successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998;177:1112-1115.
4. Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 2002;70:584-590.
5. Gioia CAC, Sousa AB, Cruz SC, et al. Effect of booster dose of serogroup B meningococcal vaccine no antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules. FEMS Immunol Med Microbiol 2005;44: 35-42.
6. Gassman C, Bauer G. Avidity determination of IgG directed against tick-borne encephalitis virus improves detection of current infections. J Med Virol 1997;51:242-251.
7. Jenun PA, Stray-Pedersen B, Gundersen AG. Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol 1997;35:1972-1977.
8. Alvarado-Esquivel C, Sethi S, Janitschke K, Hahn H, Liesenfeld O. Comparison of two commercially available avidity tests for Toxoplasma- specific OgG antibodies. Arch Med Res 2002; 33:520-523.
9. Korhonen MH, Brunstein J, Haario H, Katnikiv A, Rescaldani R, Hedman K. A new method with general diagnostic utility for the calculation of immunoglobulin avidity. Clin Diagn Lab Immunol 1999;6:725-728.
10. Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000;19:333-345.
11. Milagres LG, Ramos SR, Sacchi CT. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994;62:4419-4424.
12. Pollard AJ, Galassini R, van der Voort E. Humoral immune responses to Neisseria meningitidis in children. Infect Immun 1999;67:2441-2451.
13. Pollard AJ, Levin M. Production of low-avidity antibody by infants after infection with serogroup B meningococci. Lancet 2000;356:2065-2066.
14. Singh M, Ugozzoli M, Kazzaz J, et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine adjuvants. Vaccine 2005;24:1980-1986.
15. Fukasawa LO, Dias WO, Schenkman PF, Raw I, Tanizaki MM. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice. FEMS Immunol Med Microbiol 2004;41:205-210.
16. Kubrusly FS, Netto SL, Iortov D, Raw I, Araujo PS. A natural surfactant from pig lungs. Biotechnol Lett 2000;22:1251-1253.
17. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case control study. Int J Epidemiol 1995;24: 4419-4424.
18. Boslego J, Garcia J, Cruz C. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane vesicle vaccine in Iquiuqe, Chile. Vaccine 1995;13:821-829.
19. Tapero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281: 1541-1543.
20. Pollard AJ, Galassini R, Roupe EM, et al. Cellular immune responses to Neisseria meningitidis in children. Infect Immun 1999;67:2452-2463.
21. Pollard AJ, Galassini R, Rouppe EM, et al. Humoral immune responses to Neisseria meningitidis in chidren. Infect Immun 1999;67:2441-2451.
22. Korhonen MH, Brunstein J, Haario H, Katnikiv A, Rescaldani R, Hedmna K. A new method with general diagnostic utility for the calculation of immunoglobulin avidity. Clin Diagn Lab Immunol 1999;6:724-728.
23. Pollard AJ, Levin M. Production of low-avidity antibody after infection with serogroup B meningococci. Lancet 2000;356:265-2066.
24. Vermont CL, van Dijken HH, de Groot R, van den Dobbelsteen GP. Porin A-specific antibody avidity in patients who are convalescing from meningococcal disease. Pediatr Res 2005;58: 149-152.